Developer docs
API playgroundTry for free, no card

Search company profiles

New Day Diagnostics

Full company profile

uuid000a4sl

Namestring
New Day Diagnostics
Legal namestring
New Day Diagnostics, LLC
Company typeenum
Private
Founded yearint
2005
Descriptiontext

New Day Diagnostics, LLC is a Knoxville, Tennessee-based clinical laboratory and diagnostic development company specializing in blood-based liquid biopsy tests for early cancer detection, with a flagship focus on colorectal cancer screening. The company markets ColoHealth, a non-invasive blood test that uses Real-Time PCR detection of the methylated Septin 9 (mSEPT9) biomarker and reports 99.7% negative predictive value in clinical validation. ColoHealth is sold direct-to-consumer through colohealthy.com at a $299 fixed self-pay price and is also available to physicians via a dedicated portal with consolidated monthly billing. The company is building a broader diagnostic pipeline that includes the in-development ColoPlex Plus multi-target assay, a prostate cancer assay, the SPINEstat ankylosing spondylitis test developed with Augurex, and tests for celiac disease, H. pylori, respiratory multiplex, and hepatocellular carcinoma in collaboration with Hepion Pharmaceuticals.

The company was formed through the 2023 merger of New Day Diagnostics and EDP Biotech Corporation, followed by the September 2023 asset acquisition of Epigenomics AG, which transferred 450 patents and the Epi proColon technology into the combined entity. New Day operates a CLIA-certified high-complexity laboratory (CLIA #44D2184836) and maintains ISO 13485:2016 certification for diagnostic device design, and it monetizes laboratory capacity beyond its own products through New Day Bioresearch, a contract research organization offering assay design, analytical validation, clinical trial support, and regulatory strategy to pharmaceutical and biotech sponsors. Distribution combines direct-to-consumer e-commerce, a physician ordering portal, a Middle East distribution partnership with SehaMed Global, and a research collaboration with Daisy Genomics and the University of Tennessee aimed at next-generation epigenetic sequencing. Leadership is led by CEO Eric Mayer (since 2015) and Executive Chairman Navroze Mehta, supported by a board with prior operating experience at Welch Allyn, NextGen Healthcare, Jewelry Television, and other companies.

Short descriptiontext

New Day Diagnostics is a Knoxville-based clinical laboratory that develops and commercializes blood-based liquid biopsy diagnostics, led by its ColoHealth colorectal cancer screening test, and offers contract research services to pharmaceutical and biotech sponsors.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersKnoxville, United States
HQ citystring
Knoxville
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
blood-based diagnostics, colorectal cancer screening, liquid biopsy tests, molecular diagnostics, diagnostic CRO services
Industry3 codes
PRIMARYHLAAANAG
Liquid Biopsy & Minimal Residual Disease (MRD) Precision Testing
SECONDARYHLAIALAF
Translational Medicine & Biomarkers
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAAAMAC
Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
NAICS code3 codes
  • Medical Laboratories621511
  • In-Vitro Diagnostic Substance Manufacturing325413
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code3 codes
  • Services-Medical Laboratories8071
  • In Vitro & In Vivo Diagnostic Substances2835
  • Services-Commercial Physical & Biological Research8731
Product category
Molecular Cancer Diagnostics
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1ColoHealth Direct Sales
TypeOne Time License
Description

Direct-to-consumer sales of blood-based colorectal cancer screening test at $299 fixed self-pay price, enabling patients to order online without insurance hassles.

newdaydiagnostics.com
2Professional Laboratory Services
TypeTransaction Fee
Description

Laboratory testing services billed professionally to healthcare providers and clinics through the physician portal, including consolidated monthly invoicing for practice clients.

newdaydiagnostics.com
3CRO Services (New Day Bioresearch)
TypeProfessional Services
Description

Contract Research Organization services including assay design, analytical validation, clinical trial management, and regulatory compliance support for pharmaceutical and biotech sponsors.

newdaydiagnostics.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Pricing details2 tiers
1ColoHealth Direct - Self-Pay
ModelOne time/ perpetual licenseBilling cadencePay-as-you-go
Notes

$299 fixed self-pay price for direct-to-consumer ordering. HSA and FSA accounts accepted. No insurance required.

newdaydiagnostics.com
2ColoHealth for Physicians
ModelTransaction based/ take rateBilling cadenceMonthly
Notes

Professional billing or direct clinic invoicing with consolidated monthly billing. No per-kit transaction model.

newdaydiagnostics.com
GTM typeB2B and B2C
B2B and B2C
Offering typeServices
Services
Brand1 of 4 records shown
1ColoHealth
Description

Blood-based colorectal cancer screening test with 99.7% NPV. A non-invasive alternative to colonoscopy for average-risk adults aged 50+.

newdaydiagnostics.com
+3 more records
Core offering1 text field

New Day Diagnostics develops and commercializes blood-based molecular diagnostic tests, with its flagship ColoHealth product providing non-invasive colorectal cancer screening via Real-Time PCR detection of the methylated Septin 9 (mSEPT9) biomarker from a routine blood draw. The company also operates New Day Bioresearch, a Contract Research Organization offering end-to-end assay design, analytical validation, clinical trial management, and regulatory strategy services for pharmaceutical and biotech sponsors.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 99.7% Negative Predictive Value (NPV) in clinical validation studies
+2 more records
Product overview1 text field

New Day Diagnostics offers a portfolio of blood-based diagnostic products centered on its flagship ColoHealth test for colorectal cancer screening, complemented by a vertically integrated CRO services division (New Day Bioresearch) that provides end-to-end partnership for assay development, clinical trial management, and regulatory strategy. The commercial product lineup is led by ColoHealth (FDA-approved science, 99.7% NPV, mSEPT9 biomarker), which is available as direct-to-consumer (ColoHealth Direct) and physician-orderable (ColoHealth for Physicians) offerings. The development pipeline includes ColoPlex Plus (next-generation multi-target CRC assay), a Prostate Cancer Assay (research/discovery stage), and tests for Celiac Disease, H. pylori, and Respiratory Multiplex (COVID-Flu-RSV) developed under partnership agreements. New Day Bioresearch CRO services support external pharmaceutical and biotech sponsors across oncology, infectious diseases, gastrointestinal disorders, and women's health.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-01-08
Description

Strategic research collaboration to advance next-generation epigenetic sequencing and liquid biopsy tools for early colorectal cancer detection. Combines New Day's clinically validated CRC liquid biopsy technology with Daisy Genomics' physics-based optical sequencing platform. Research conducted across New Day's CLIA-certified laboratory and University of Tennessee facilities.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-01-08
Description

Multi-institution collaboration supporting next-generation epigenetic sequencing research. Partners aim to leverage the university's manufacturing and research infrastructure, including the Institute for Advanced Materials & Manufacturing, to generate foundational clinical data for scalable cancer screening tools.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-01-08
Description

Collaboration supporting advancement of liquid biopsy tools for early colorectal cancer detection, focused on reaching underserved patient populations through multi-institution alliance.

4SehaMed Global Ltd.
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-08-20
Description

Strategic distribution agreement to launch ColoHealth blood test for colorectal cancer screening across the Middle East. SehaMed is a Bristol-based MedTech platform connecting manufacturers, distributors, and hospitals worldwide, enabling entry into high-growth international markets.

newdaydiagnostics.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-05-07
Description

Binding letter of intent to commercialize tests for Celiac Disease, respiratory multiplex (COVID-Flu-RSV), H. pylori, and hepatocellular carcinoma (HCC). Hepion is a clinical-stage biopharmaceutical company developing treatments for NASH and HCC.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-05-30
Description

Collaboration to launch SPINEstat, a first-of-its-kind multiplex biomarker assay for transforming the early diagnosis and management of ankylosing spondylitis. Augurex is based in Vancouver, BC, Canada.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2023-07-24
Description

Asset purchase agreement to acquire substantially all assets and intellectual property from Berlin-based Epigenomics AG. Includes 450 patents and proprietary biomarker technology for methylated DNA detection, including Epi proColon CRC screening test.

8EDP Biotech Corp.
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-07-05
Description

Asset merger combining EDP Biotech's position as established specialty diagnostic developer and CRO with New Day Diagnostics' pipeline and commercialization capabilities, forming a vertically integrated diagnostics powerhouse.

newdaydiagnostics.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

CellMax Life develops blood-based ctDNA tests for early cancer detection including colorectal, prostate, and other cancers, putting it in direct technological adjacency with NDD's mSEPT9 and prostate cancer pipeline programs.

TypeDirect peer
Description

Freenome is developing a multi-analyte blood test for early CRC detection using methylation and other biomarkers, going head-to-head with NDD's mSEPT9 and future ColoPlex Plus multi-target assay in the same clinical and commercial channel.

TypeDirect peer
Description

Guardant Health's Shield is a blood-based ctDNA CRC screening test approved by FDA and covered by Medicare, directly competing with ColoHealth's value proposition. Guardant also pursues multi-cancer detection, mirroring NDD's stated liquid biopsy platform ambitions.

TypeRegional player
Description

Singlera Genomics is a Shanghai-based liquid biopsy and early cancer detection developer pursuing methylation-based blood tests similar to NDD's mSEPT9 technology. It is relevant as a regional peer addressing Asian CRC screening markets where NDD has signaled interest.

TypeOthers
Description

Bio-Techne provides protein-based research and diagnostic reagents and assay kits that overlap with NDD's Luminex xMAP-based ColoPlex and SPINEstat multiplex biomarker assays, sitting in the same biomarker tools and diagnostic reagents supply chain.

TypeBroad incumbent
Description

NeoGenomics operates CLIA-certified specialty oncology laboratories offering biomarker testing services to oncologists, pharma, and CRO clients, directly paralleling NDD's New Day Bioresearch CRO services arm and clinical biomarker testing offering.

7GRAIL
TypeEmerging player
Description

GRAIL's Galleri is a multi-cancer early detection (MCED) blood test that overlaps with NDD's stated 10-year goal of a universal liquid biopsy platform. Both companies pursue methylation-based detection of cell-free DNA, though GRAIL focuses on multi-cancer vs. NDD's CRC-first approach.

TypeBroad incumbent
Description

Exact Sciences markets Cologuard, the dominant non-invasive CRC screening test (stool DNA-based), and has scaled to billions in revenue with full Medicare coverage. It is the primary commercial benchmark for any non-invasive CRC screening entrant, including NDD's blood-based ColoHealth.

TypeBroad incumbent
Description

Quest Diagnostics operates one of the largest U.S. medical laboratory networks including molecular and specialty oncology testing. It is a comparable CLIA-certified lab services peer and also a potential channel partner for ColoHealth physician volume.

TypeBroad incumbent
Description

Labcorp's diagnostics and Covance CRO arms parallel NDD's two-sided commercial model (clinical lab + CRO services), and Labcorp's scale and payer contracts represent both a competitive threat and a potential distribution channel for ColoHealth.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles19 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

New Day Diagnostics

Molecular Cancer Diagnosticsnewdaydiagnostics.com

New Day Diagnostics is a Knoxville-based clinical laboratory that develops and commercializes blood-based liquid biopsy diagnostics, led by its ColoHealth colorectal cancer screening test, and offers contract research services to pharmaceutical and biotech sponsors.

What New Day Diagnostics does

New Day Diagnostics, LLC is a Knoxville, Tennessee-based clinical laboratory and diagnostic development company specializing in blood-based liquid biopsy tests for early cancer detection, with a flagship focus on colorectal cancer screening. The company markets ColoHealth, a non-invasive blood test that uses Real-Time PCR detection of the methylated Septin 9 (mSEPT9) biomarker and reports 99.7% negative predictive value in clinical validation. ColoHealth is sold direct-to-consumer through colohealthy.com at a $299 fixed self-pay price and is also available to physicians via a dedicated portal with consolidated monthly billing. The company is building a broader diagnostic pipeline that includes the in-development ColoPlex Plus multi-target assay, a prostate cancer assay, the SPINEstat ankylosing spondylitis test developed with Augurex, and tests for celiac disease, H. pylori, respiratory multiplex, and hepatocellular carcinoma in collaboration with Hepion Pharmaceuticals.

The company was formed through the 2023 merger of New Day Diagnostics and EDP Biotech Corporation, followed by the September 2023 asset acquisition of Epigenomics AG, which transferred 450 patents and the Epi proColon technology into the combined entity. New Day operates a CLIA-certified high-complexity laboratory (CLIA #44D2184836) and maintains ISO 13485:2016 certification for diagnostic device design, and it monetizes laboratory capacity beyond its own products through New Day Bioresearch, a contract research organization offering assay design, analytical validation, clinical trial support, and regulatory strategy to pharmaceutical and biotech sponsors. Distribution combines direct-to-consumer e-commerce, a physician ordering portal, a Middle East distribution partnership with SehaMed Global, and a research collaboration with Daisy Genomics and the University of Tennessee aimed at next-generation epigenetic sequencing. Leadership is led by CEO Eric Mayer (since 2015) and Executive Chairman Navroze Mehta, supported by a board with prior operating experience at Welch Allyn, NextGen Healthcare, Jewelry Television, and other companies.

New Day Diagnostics firmographics

Firmographics
Name
New Day Diagnostics
Legal name
New Day Diagnostics, LLC
Website
https://newdaydiagnostics.com
Company type
Private
Founded year
2005
Operating status
Operating
Headcount range
11–50 employees
Short description
New Day Diagnostics is a Knoxville-based clinical laboratory that develops and commercializes blood-based liquid biopsy diagnostics, led by its ColoHealth colorectal cancer screening test, and offers contract research services to pharmaceutical and biotech sponsors.
Ownership category
akta.pro rank

New Day Diagnostics industry classification

Industry
Product category
Molecular Cancer Diagnostics
NAICS
Medical Laboratories (621511), In-Vitro Diagnostic Substance Manufacturing (325413), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAANAG
Liquid Biopsy & Minimal Residual Disease (MRD) Precision Testing
SECONDARYHLAIALAF
Translational Medicine & Biomarkers
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAAAMAC
Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics

Keywords

  • Blood-based diagnostics
  • Colorectal cancer screening
  • Liquid biopsy tests
  • Molecular diagnostics
  • Diagnostic CRO services

Where New Day Diagnostics is headquartered

Location

Headquarters

HQ city
Knoxville
HQ country
United States
HQ region
North America

Offices1 record

Markets served

New Day Diagnostics business model

Business model
GTM type
B2B and B2C
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. ColoHealth Direct Sales: Direct-to-consumer sales of blood-based colorectal cancer screening test at $299 fixed self-pay price, enabling patients to order online without insurance hassles.
  2. Professional Laboratory Services: Laboratory testing services billed professionally to healthcare providers and clinics through the physician portal, including consolidated monthly invoicing for practice clients.
  3. CRO Services (New Day Bioresearch): Contract Research Organization services including assay design, analytical validation, clinical trial management, and regulatory compliance support for pharmaceutical and biotech sponsors.

Pricing tiers

ModelBillingPrice
One time/ perpetual licensePay-as-you-goColoHealth Direct - Self-Pay
Transaction based/ take rateMonthlyColoHealth for Physicians

Go-to-market motion3 records

Distribution channels4 records

Marketing channels3 records

New Day Diagnostics product offering

Product offering

Core offering

New Day Diagnostics develops and commercializes blood-based molecular diagnostic tests, with its flagship ColoHealth product providing non-invasive colorectal cancer screening via Real-Time PCR detection of the methylated Septin 9 (mSEPT9) biomarker from a routine blood draw. The company also operates New Day Bioresearch, a Contract Research Organization offering end-to-end assay design, analytical validation, clinical trial management, and regulatory strategy services for pharmaceutical and biotech sponsors.

Product overview

New Day Diagnostics offers a portfolio of blood-based diagnostic products centered on its flagship ColoHealth test for colorectal cancer screening, complemented by a vertically integrated CRO services division (New Day Bioresearch) that provides end-to-end partnership for assay development, clinical trial management, and regulatory strategy. The commercial product lineup is led by ColoHealth (FDA-approved science, 99.7% NPV, mSEPT9 biomarker), which is available as direct-to-consumer (ColoHealth Direct) and physician-orderable (ColoHealth for Physicians) offerings. The development pipeline includes ColoPlex Plus (next-generation multi-target CRC assay), a Prostate Cancer Assay (research/discovery stage), and tests for Celiac Disease, H. pylori, and Respiratory Multiplex (COVID-Flu-RSV) developed under partnership agreements. New Day Bioresearch CRO services support external pharmaceutical and biotech sponsors across oncology, infectious diseases, gastrointestinal disorders, and women's health.

Differentiator

Problem solved

Functional benefit

Brands

  • ColoHealth: Blood-based colorectal cancer screening test with 99.7% NPV. A non-invasive alternative to colonoscopy for average-risk adults aged 50+.
  • New Day Bioresearch
  • ColoPlex
  • ColoPlex Plus

Quantifiable outcome

  • 99.7% Negative Predictive Value (NPV) in clinical validation studies
  • +2 more outcomes

Companies that use New Day Diagnostics

Customer profile

Named customers2 records

Segments4 records

Ideal customer profiles4 records

New Day Diagnostics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature4 records

New Day Diagnostics partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered core.

  • Daisy Genomics Inc.coreStrategic or Co-development Partner · 8 January 2026Strategic research collaboration to advance next-generation epigenetic sequencing and liquid biopsy tools for early colorectal cancer detection. Combines New Day's clinically validated CRC liquid biopsy technology with Daisy Genomics' physics-based optical sequencing platform. Research conducted across New Day's CLIA-certified laboratory and University of Tennessee facilities.
  • University of TennesseecoreStrategic or Co-development Partner · 8 January 2026Multi-institution collaboration supporting next-generation epigenetic sequencing research. Partners aim to leverage the university's manufacturing and research infrastructure, including the Institute for Advanced Materials & Manufacturing, to generate foundational clinical data for scalable cancer screening tools.
  • East Tennessee Health Innovation AlliancecoreStrategic or Co-development Partner · 8 January 2026Collaboration supporting advancement of liquid biopsy tools for early colorectal cancer detection, focused on reaching underserved patient populations through multi-institution alliance.
  • SehaMed Global Ltd.coreChannel Partner/ Reseller/ Distributor · 20 August 2025Strategic distribution agreement to launch ColoHealth blood test for colorectal cancer screening across the Middle East. SehaMed is a Bristol-based MedTech platform connecting manufacturers, distributors, and hospitals worldwide, enabling entry into high-growth international markets.
  • Hepion PharmaceuticalscoreStrategic or Co-development Partner · 7 May 2025Binding letter of intent to commercialize tests for Celiac Disease, respiratory multiplex (COVID-Flu-RSV), H. pylori, and hepatocellular carcinoma (HCC). Hepion is a clinical-stage biopharmaceutical company developing treatments for NASH and HCC.
  • AugurexcoreStrategic or Co-development Partner · 30 May 2024Collaboration to launch SPINEstat, a first-of-its-kind multiplex biomarker assay for transforming the early diagnosis and management of ankylosing spondylitis. Augurex is based in Vancouver, BC, Canada.
  • Epigenomics AGcoreTechnology or Integration · 24 July 2023Asset purchase agreement to acquire substantially all assets and intellectual property from Berlin-based Epigenomics AG. Includes 450 patents and proprietary biomarker technology for methylated DNA detection, including Epi proColon CRC screening test.
  • EDP Biotech Corp.coreStrategic or Co-development Partner · 5 July 2023Asset merger combining EDP Biotech's position as established specialty diagnostic developer and CRO with New Day Diagnostics' pipeline and commercialization capabilities, forming a vertically integrated diagnostics powerhouse.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

New Day Diagnostics competitors and assessment

Company assessment

Emerging players

  • CellMax Life: CellMax Life develops blood-based ctDNA tests for early cancer detection including colorectal, prostate, and other cancers, putting it in direct technological adjacency with NDD's mSEPT9 and prostate cancer pipeline programs.
  • GRAIL: GRAIL's Galleri is a multi-cancer early detection (MCED) blood test that overlaps with NDD's stated 10-year goal of a universal liquid biopsy platform. Both companies pursue methylation-based detection of cell-free DNA, though GRAIL focuses on multi-cancer vs. NDD's CRC-first approach.

Direct peers

  • Freenome: Freenome is developing a multi-analyte blood test for early CRC detection using methylation and other biomarkers, going head-to-head with NDD's mSEPT9 and future ColoPlex Plus multi-target assay in the same clinical and commercial channel.
  • Guardant Health: Guardant Health's Shield is a blood-based ctDNA CRC screening test approved by FDA and covered by Medicare, directly competing with ColoHealth's value proposition. Guardant also pursues multi-cancer detection, mirroring NDD's stated liquid biopsy platform ambitions.

Regional players

  • Singlera Genomics: Singlera Genomics is a Shanghai-based liquid biopsy and early cancer detection developer pursuing methylation-based blood tests similar to NDD's mSEPT9 technology. It is relevant as a regional peer addressing Asian CRC screening markets where NDD has signaled interest.

Others

  • Bio-Techne: Bio-Techne provides protein-based research and diagnostic reagents and assay kits that overlap with NDD's Luminex xMAP-based ColoPlex and SPINEstat multiplex biomarker assays, sitting in the same biomarker tools and diagnostic reagents supply chain.

Broad incumbents

  • NeoGenomics: NeoGenomics operates CLIA-certified specialty oncology laboratories offering biomarker testing services to oncologists, pharma, and CRO clients, directly paralleling NDD's New Day Bioresearch CRO services arm and clinical biomarker testing offering.
  • Exact Sciences: Exact Sciences markets Cologuard, the dominant non-invasive CRC screening test (stool DNA-based), and has scaled to billions in revenue with full Medicare coverage. It is the primary commercial benchmark for any non-invasive CRC screening entrant, including NDD's blood-based ColoHealth.
  • Quest Diagnostics: Quest Diagnostics operates one of the largest U.S. medical laboratory networks including molecular and specialty oncology testing. It is a comparable CLIA-certified lab services peer and also a potential channel partner for ColoHealth physician volume.
  • Labcorp/Covance: Labcorp's diagnostics and Covance CRO arms parallel NDD's two-sided commercial model (clinical lab + CRO services), and Labcorp's scale and payer contracts represent both a competitive threat and a potential distribution channel for ColoHealth.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

New Day Diagnostics social profiles

Digital presence

New Day Diagnostics compliance and trust

Trust signal

Compliance2 records

New Day Diagnostics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

New Day Diagnostics leadership team

Management profile

Number of profiles

Profiles19 records

New Day Diagnostics funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

New Day Diagnostics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about New Day Diagnostics

What does New Day Diagnostics do?

New Day Diagnostics develops and commercializes blood-based molecular diagnostic tests, with its flagship ColoHealth product providing non-invasive colorectal cancer screening via Real-Time PCR detection of the methylated Septin 9 (mSEPT9) biomarker from a routine blood draw. The company also operates New Day Bioresearch, a Contract Research Organization offering end-to-end assay design, analytical validation, clinical trial management, and regulatory strategy services for pharmaceutical and biotech sponsors.

Is New Day Diagnostics a public or private company?

New Day Diagnostics is a private company. It is classified as venture growth investor backed and is currently operating.

When was New Day Diagnostics founded?

New Day Diagnostics was founded in 2005. It employs 11 to 50 people.

Where is New Day Diagnostics based?

New Day Diagnostics is headquartered in Knoxville, United States, in the North America region.

How does New Day Diagnostics make money?

Three revenue lines are on record. ColoHealth Direct Sales are the primary driver. The others are professional Laboratory Services and CRO Services (New Day Bioresearch).

Who are New Day Diagnostics's main competitors?

Emerging players on record are CellMax Life and GRAIL. Direct peers are Freenome and Guardant Health. Singlera Genomics is listed as a regional player. Bio-Techne is listed as an others. Broad incumbents are NeoGenomics, Exact Sciences, Quest Diagnostics and Labcorp/Covance.

Does New Day Diagnostics have an API?

No public API is recorded for New Day Diagnostics.

What industry is New Day Diagnostics in?

New Day Diagnostics's product category is Molecular Cancer Diagnostics. Its primary akta.pro industry code is HLAAANAG, Liquid Biopsy & Minimal Residual Disease (MRD) Precision Testing, with a secondary code of HLAIALAF, Translational Medicine & Biomarkers. Its NAICS code is 621511 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioSpaceNew Day Diagnostics Highlights Rising Early-Onset Colorectal Cancer Rates During Colorectal Cancer Awareness MonthNew Day Diagnostics is using Colorectal Cancer Awareness Month to raise awareness about the rising rates of early-onset colorectal cancer in individuals under 50, highlighting a growing public health gap as traditional screening methods often miss this younger demographic. A peer-reviewed study published in Cancer Research Communications demonstrated that the company's blood-based biomarker test detecting methylated Septin9 (mSEPT9) achieved 90.8% sensitivity and 88.9% specificity in detecting colorectal cancer in patients under 50. The company is promoting its ColoHealth Direct laboratory-developed test as an accessible, minimally invasive alternative to colonoscopy or stool-based testing to help close the screening gap.EIN PresswireNew Day Diagnostics Highlights Rising Early-Onset Colorectal Cancer Rates During Colorectal Cancer Awareness MonthNew Day Diagnostics is using Colorectal Cancer Awareness Month to raise awareness about the increasing rates of early-onset colorectal cancer in individuals under 50 and promote its blood-based screening test ColoHealth Direct. A peer-reviewed study published in Cancer Research Communications demonstrated that the mSEPT9 biomarker achieved 90.8% sensitivity and 88.9% specificity in detecting colorectal cancer in younger patients. The company positions its test as an accessible alternative to traditional colonoscopy or stool-based testing to address the public health gap for those outside conventional screening pathways.The Northwest Florida Daily NewsDaisy Genomics and New Day Diagnostics Partner to Advance CRC Detection With University of Tennessee SupportDaisy Genomics Inc. and New Day Diagnostics announced a strategic research collaboration, partnered with the University of Tennessee and the East Tennessee Health Innovation Alliance, to advance next-generation epigenetic sequencing and liquid biopsy tools for early colorectal cancer detection. The collaboration will combine New Day's clinically validated CRC liquid biopsy technology with Daisy Genomics' physics-based optical sequencing platform across New Day's CLIA-certified laboratory and the university's facilities. The partners aim to leverage this multi-institution alliance to generate foundational clinical data for scalable cancer screening tools capable of reaching underserved patient populations.Newport Daily NewsDaisy Genomics and New Day Diagnostics Partner to Advance CRC Detection With University of Tennessee SupportDaisy Genomics Inc. and New Day Diagnostics have announced a strategic research collaboration in partnership with the University of Tennessee and the East Tennessee Health Innovation Alliance to advance next-generation epigenetic sequencing and liquid biopsy tools for early colorectal cancer detection. The collaboration will combine New Day's clinically validated CRC liquid biopsy technology with Daisy Genomics' physics-based sequencing platform, with research conducted across New Day's CLIA-certified laboratory and University of Tennessee facilities. The partners aim to leverage the university's manufacturing and research infrastructure to develop scalable screening approaches capable of reaching underserved patient populations.Teknovation.bizNew Day Diagnostics is at the center of a new research partnership focused on cancer diagnosisNew Day Diagnostics has formed a collaborative research partnership with the University of Tennessee, Knoxville, and Daisy Genomics Inc. to advance cancer diagnosis technologies. The agreement combines New Day's liquid biopsy technology with Daisy Genomics' sequencing platform to develop more scalable and accurate early cancer screening methods.The Daily News JournalDaisy Genomics and New Day Diagnostics Partner to Advance CRC Detection With University of Tennessee SupportDaisy Genomics Inc. and New Day Diagnostics have announced a strategic research collaboration, supported by the University of Tennessee and the East Tennessee Health Innovation Alliance, to advance next-generation epigenetic sequencing and liquid biopsy tools for early colorectal cancer detection. The partnership combines New Day's clinically validated CRC liquid biopsy technology with Daisy Genomics' physics-based sequencing platform, with research to be conducted at New Day's CLIA-certified laboratory and UT facilities including the Institute for Advanced Materials & Manufacturing. The multi-institution collaboration aims to generate foundational data demonstrating direct detection of epigenetic signals without chemical amplification, with potential to expand advanced cancer screening to underserved patient populations.Clinical Lab ProductsDaisy Genomics, New Day Diagnostics Partner on Colorectal Cancer Detection PlatformDaisy Genomics and New Day Diagnostics have announced a strategic research collaboration with the University of Tennessee and the East Tennessee Health Innovation Alliance to develop next-generation epigenetic sequencing and liquid biopsy tools for early colorectal cancer detection. The partnership will integrate New Day's clinically validated CRC liquid biopsy technology with Daisy Genomics' physics-based sequencing platform to enable earlier, more accurate, and more scalable cancer screening. Colorectal cancer is the second deadliest cancer in the US, and the collaboration aims to make screening more accessible through streamlined, affordable workflows capable of detecting critical epigenetic changes directly.Columbia Daily TribuneDaisy Genomics and New Day Diagnostics Partner to Advance CRC Detection With University of Tennessee SupportDaisy Genomics Inc. and New Day Diagnostics have announced a strategic research collaboration, in partnership with the University of Tennessee and the East Tennessee Health Innovation Alliance, to develop next-generation epigenetic sequencing and liquid biopsy tools for early colorectal cancer detection. The partnership combines New Day's clinically validated CRC liquid biopsy technology with Daisy Genomics' physics-based sequencing platform, with research to be conducted at New Day's CLIA-certified laboratory and University of Tennessee facilities. The multi-institution collaboration aims to leverage the university's research infrastructure and materials science expertise to generate foundational clinical data and expand access to scalable cancer screening tools.Knoxville News SentinelDaisy Genomics and New Day Diagnostics Partner to Advance CRC Detection With University of Tennessee SupportDaisy Genomics and New Day Diagnostics announced a research collaboration with the University of Tennessee to develop epigenetic sequencing and liquid biopsy tools for colorectal cancer detection. The partnership combines New Day's clinically validated liquid biopsy with Daisy Genomics' physics-based sequencing platform to generate foundational data on direct epigenetic signal detection.The Topeka Capital-JournalDaisy Genomics and New Day Diagnostics Partner to Advance CRC Detection With University of Tennessee SupportDaisy Genomics and New Day Diagnostics have announced a strategic research collaboration, in partnership with the University of Tennessee and the East Tennessee Health Innovation Alliance, to advance colorectal cancer detection using epigenetic sequencing and liquid biopsy technologies. The collaboration will combine New Day's clinically validated CRC liquid biopsy technology with Daisy Genomics' physics-based sequencing platform to generate foundational data for earlier, more accurate, and scalable cancer screening. The partners aim to leverage the University of Tennessee's research infrastructure to develop scalable screening approaches and position Tennessee as a national leader in next-generation cancer detection and precision health innovation.